Head and neck cancer

MD Mody, JW Rocco, SS Yom, RI Haddad, NF Saba - The Lancet, 2021 - thelancet.com
Head and neck cancer is the seventh most common type of cancer worldwide and comprise
of a diverse group of tumours affecting the upper aerodigestive tract. Although many different …

Head and neck squamous cell carcinoma

DE Johnson, B Burtness, CR Leemans… - Nature reviews Disease …, 2020 - nature.com
Most head and neck cancers are derived from the mucosal epithelium in the oral cavity,
pharynx and larynx and are known collectively as head and neck squamous cell carcinoma …

[HTML][HTML] Reviewing the epidemiology of head and neck cancer: definitions, trends and risk factors

M Gormley, G Creaney, A Schache, K Ingarfield… - British Dental …, 2022 - nature.com
Introduction Head and neck cancer appears to be increasing in incidence, with potential
changes in aetiology proposed. This paper aims to provide a narrative overview of the …

NCCN Guidelines® insights: Head and neck cancers, version 1.2022: Featured updates to the NCCN guidelines

JJ Caudell, ML Gillison, E Maghami, S Spencer… - Journal of the National …, 2022 - jnccn.org
The NCCN Guidelines for Head and Neck Cancers address tumors arising in the oral cavity
(including mucosal lip), pharynx, larynx, and paranasal sinuses. Occult primary cancer …

Head and neck cancers, version 2.2020, NCCN clinical practice guidelines in oncology

DG Pfister, S Spencer, D Adelstein, D Adkins… - Journal of the National …, 2020 - jnccn.org
Treatment is complex for patients with head and neck (H&N) cancers with specific site of
disease, stage, and pathologic findings guiding treatment decision-making. Treatment …

Prognostic implications of p16 and HPV discordance in oropharyngeal cancer (HNCIG-EPIC-OPC): a multicentre, multinational, individual patient data analysis

H Mehanna, M Taberna, C Von Buchwald… - The Lancet …, 2023 - thelancet.com
Background p16 INK4a (p16) immunohistochemistry is the most widely used biomarker
assay for inferring HPV causation in oropharyngeal cancer in clinical and trial settings …

Oral diseases: a global public health challenge

MA Peres, LMD Macpherson, RJ Weyant, B Daly… - The Lancet, 2019 - thelancet.com
Oral diseases are among the most prevalent diseases globally and have serious health and
economic burdens, greatly reducing quality of life for those affected. The most prevalent and …

Role of PI3K/AKT pathway in cancer: the framework of malignant behavior

N Jiang, Q Dai, X Su, J Fu, X Feng, J Peng - Molecular biology reports, 2020 - Springer
Given that the PI3K/AKT pathway has manifested its compelling influence on multiple
cellular process, we further review the roles of hyperactivation of PI3K/AKT pathway in …

Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled …

H Mehanna, M Robinson, A Hartley, A Kong, B Foran… - The Lancet, 2019 - thelancet.com
Background The incidence of human papillomavirus (HPV)-positive oropharyngeal cancer,
a disease affecting younger patients, is rapidly increasing. Cetuximab, an epidermal growth …

The changing therapeutic landscape of head and neck cancer

JD Cramer, B Burtness, QT Le, RL Ferris - Nature reviews Clinical …, 2019 - nature.com
Head and neck cancers are a heterogeneous collection of malignancies of the upper
aerodigestive tract, salivary glands and thyroid. In this Review, we primarily focus on the …